{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021862","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.227746+00:00","generated_at":"2026-06-22T09:44:02.762997+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Design Therapeutics reports Q3 net loss $17.7M; cash $344.2M; DT-216 Phase 1 SAD data in Dec 2022","bullets":["Net loss of $17.7M for Q3 2022; R&D expenses $14.3M, G&A expenses $4.9M.","Cash, equivalents and securities of $344.2M as of Sept 30, 2022, supporting multi-year runway.","Initial data from DT-216 single-ascending dose Phase 1 for Friedreich Ataxia expected Dec 2022.","Multiple-ascending dose Phase 1 dosing initiated; completion anticipated mid-2023.","DM1 GeneTAC program preclinical; clinical development expected to begin in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021862","json":"https://secwatch.observer/filing/0000950170-22-021862.json","markdown":"https://secwatch.observer/filing/0000950170-22-021862.md","text":"https://secwatch.observer/filing/0000950170-22-021862.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000095017022021862/0000950170-22-021862-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000095017022021862/dsgn-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:44:02.762997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aaa1bd5952a9ab62500b92bd2819d32272ab0987","claim":"Design Therapeutics, Inc. reported third quarter 2022 results: net income Net loss was $17.7 million.","evidence_excerpt":"Design Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807120/000095017022021862/0000950170-22-021862-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2022"},{"label":"Net income","value":"Net loss was $17.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}